Many major pharma companies are making bets in the digital therapeutics space in one way or another. Some companies see it as a core part of their future, as they launch new DTx solutions as standalone products, versus others are excited about the potential of DTx to perfectly complement their portfolio of drugs, as a way to improve the outcomes for their patients. Underpinning the success of these strategies is the ability for these companies to successfully engage providers and patients in these new models of care. In this webinar, we bring together a diverse set of perspectives to discuss the DTx landscape and the challenges that pharma companies are facing.
In this webinar, we covered topics including: